15+ years in clinical research
30+
Clinical studies
8+
Therapeutic areas
From rare pediatric diseases to behavioral neuroscience, substance use to genomics, my research career spans the full spectrum of clinical investigation with a throughline of health equity and advocacy at every stage.
Current work
I currently serve as Research Manager at a pediatric neurodiversity technology lab in Seattle, where our work sits at the intersection of autism spectrum disorder research, biomarker development, and innovative technology interventions. The lab uses eye tracking and near infrared spectroscopy to track treatment effects, understand developmental heterogeneity, and predict clinical outcomes.
We develop mobile applications, video games, social robots, and virtual reality systems as next-generation sensing and therapeutic tools. My role spans operational leadership, data management, regulatory compliance, and driving health equity initiatives across all active studies.
Peer-reviewed work
Prior to 2019
The following studies represent my clinical research coordination experience at a major pediatric academic medical center in Seattle, spanning rare diseases, neurology, dermatology, pulmonology, nephrology, and more.
Phase 2, randomized, double-blind, sham-controlled study of ISIS 396443 (BIIB058) administered intrathecally in subjects with spinal muscular atrophy
Expanded Access Program to provide Nusinersen to patients with infantile-onset spinal muscular atrophy
Open-label study to assess efficacy, safety, tolerability, and pharmacokinetics of ISIS 396443 in presymptomatic spinal muscular atrophy
Randomized, double-blind, placebo-controlled study of SAGE 547 injection in super-refractory status epilepticus
Collaborative Genomic Studies of Tourette Disorder
Multicenter, open-label study of LCZ696 followed by randomized, double-blind, active-controlled study evaluating efficacy and safety in pediatric heart failure due to systemic left ventricle systolic dysfunction
Phase 2, multi-centre, open-label study evaluating efficacy and safety of WTX101 in newly diagnosed Wilson Disease patients with 12-month extension
Multi-center study for assessment of copper parameters in Wilson Disease subjects on standard of care treatment
Phase 1/2 open-label study investigating safety, pharmacokinetics, and pharmacodynamics of intravenous AEB1102 in Arginase I deficiency
Neonatal Anesthesia Biomarkers Study
Phase 3, multi-center, randomized, double-blind, placebo-controlled study of SD-101 cream in Epidermolysis Bullosa
Open label multi-center extension study evaluating long-term safety of Zorblisa (SD-101-6.0) in Epidermolysis Bullosa
Phase 2/3 study investigating pharmacokinetics, safety, and efficacy of dupilumab in patients aged 6 months to under 6 years with severe atopic dermatitis
CureGN: Cure Glomerulonephropathy Network
The Nephrotic Syndrome Study Network (NEPTUNE)
Alterations in the Microbiome of Children with Nephrolithiasis
Development of an Observer Reported Outcome of Respiratory Signs for Young Children with Cystic Fibrosis
EPIC Observational Study: Longitudinal Assessment of Risk Factors and Impact of P. aeruginosa Acquisition in Children with CF
Pilot Observational Study for Standardized Treatment of Pulmonary Exacerbations in Cystic Fibrosis
Spirometer-assisted High Resolution Computerized Tomography (HRCT): Pilot Study
Prevalence and clinical significance of S. aureus small colony variants in children and adolescents with cystic fibrosis
Two-Part Multicenter Prospective Longitudinal Study of CFTR-Dependent Disease Profiling in Cystic Fibrosis (PROSPECT)
Impact of Child Life Intervention during Outpatient Cystic Fibrosis Clinic Procedure: A Pilot Study
Testing a Multifactorial Caries Model for Pediatric Patients with Cystic Fibrosis
CTN0051: Extended Release Naltrexone vs. Buprenorphine (Clinical Trials Network)
CTN0048: Cocaine Use Reduction with Buprenorphine (Clinical Trials Network)
Buprenorphine Pilot Project
Buprenorphine Post-Market Surveillance Study
Genomics and Native Communities: Perspectives, Ethics, and Engagement
Impact of Audio-Recorded Discharge Instructions on Confidence and Comprehension Among Limited English Proficient Parents: A Pilot Randomized Trial
Sleep and Ecological Factors in Infants with Craniofacial Conditions (ECOSleep)
Phase 2, multi-center, randomized, double-blind, 24-week, placebo-controlled study of Balovaptan in children and adolescents age 5-17 with Autism Spectrum Disorder
Phase 3, randomized, double-blind, placebo-controlled efficacy and safety study of Balovaptan in adults with autism spectrum disorders with 2-year open-label extension